TSVT - 2seventy bio, Inc.

QQQ $ 432.10 $ -1.05 (-0.24 %)

DIA $ 383.37 $ 0.24 (0.06 %)

SPY $ 509.91 $ -0.35 (-0.07 %)

TLT $ 88.53 $ -0.13 (-0.15 %)

GLD $ 215.63 $ -0.42 (-0.19 %)

Previous Close

$ 4.255

Open

$ 4.24

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 4.24 - $ 4.32

52 Week Range

$ 1.54 - $ 12.69

Volume

311,544

Average Volume

Market Cap

209.67M

Beta (5Y Monthly)

$ 1.92

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-07-2024	12-31-2023	10-K
2	11-14-2023	09-30-2023	10-Q
3	08-14-2023	06-30-2023	10-Q
4	05-10-2023	03-31-2023	10-Q
5	03-16-2023	12-31-2022	10-K
6	11-07-2022	09-30-2022	10-Q
7	08-10-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-22-2022	12-31-2021	10-K
10	12-01-2021	09-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies

FDA Mandates "Boxed Warning" For Bristol M...
04/19/2024 13:28:52

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

2Seventy Bio Said Co, Bristol Myers Squibb...
04/09/2024 11:06:30

Citigroup Maintains Buy on 2seventy bio, R...
04/08/2024 22:12:29

Citigroup analyst Samantha Semenkow maintains 2seventy bio (NASDAQ:TSVT) with a Buy and raises the price target from $9 to $12.

fda-approves-bristol-myers2seventy-bios-abecma-for-earlier-use-in-pretreated-blood-cancer-patients-with-updated-boxed-warning-on-secondary-cancer

FDA Approves Bristol-Myers/2seventy Bio's ...
04/05/2024 17:37:32

FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior ...

At An Estimated Median Duration Of Follow-...
04/05/2024 13:09:02

U.S. FDA Approves Bristol Myers Squibb And...
04/05/2024 13:07:51

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in r...

2seventy bio Adds Eli Casdin And Charles N...
03/20/2024 21:12:59

Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunop...

why-science-applications-international-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Science Applications International Sha...
03/18/2024 18:37:43

Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company r...

fda-adcomm-favors-expanded-use-of-johnson--johnson-bristol-myers-car-t-therapies-for-type-of-blood-cancer

FDA Adcomm Favors Expanded Use Of Johnson ...
03/18/2024 14:16:36

FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory m...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
03/18/2024 13:05:55

Market-Moving News for March 18th
03/18/2024 12:44:18

NVEI: 33% | Nuvei share are trading higher following a report indicating the company is in buyout talks with Advent Internation...

Wedbush Reiterates Neutral on 2seventy bio...
03/18/2024 12:39:13

Wedbush analyst David Nierengarten reiterates 2seventy bio (NASDAQ:TSVT) with a Neutral and maintains $5 price target.

why-nuvei-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket

Why Nuvei Shares Are Trading Higher By Aro...
03/18/2024 12:06:11

Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in...

Reported Saturday, FDA Advisory Committee ...
03/18/2024 06:37:02

The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been...

Trading Halt: Halt status updated at 6:55:...
03/15/2024 22:55:06

Trading Halt: Halted at 1:00:00 p.m. ET - ...
03/15/2024 17:00:04

why-cardlytics-shares-are-trading-higher-by-around-37-here-are-20-stocks-moving-premarket

Why Cardlytics Shares Are Trading Higher B...
03/15/2024 12:13:23

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-ex...

arcellxs-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson--johnsons-multiple-myeloma-cell-therapies-morgan-stanley

Arcellx's Lead Asset Can Potentially Outpe...
03/07/2024 19:52:19

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differenti...

2seventy bio Q4 EPS $(1.11) Misses $(0.99)...
03/05/2024 12:04:06

2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.99...

Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...